
Actively recruiting clinical studies with PD-1/PD-L1 inhibitors combined with immunosensitizing therapies in patients with advanced, recurrent or metastatic head and neck squamous-cell carcinoma.

The atezolizumab and bevacizumab arm will be compared in the phase II study part with the docetaxel, cisplatin or carboplatin and bevacizumab arm and the docetaxel, cisplatin or carboplatin and cetuximab arm.CAR-NK: Chimeric antigen receptor–natural killer; PBMC: Peripheral blood mononuclear cell; RT: Radiotherapy; SBRT: Stereotactic body radiotherapy.